TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07746687: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Inadequately Controlled Moderate

Sponsor: Janssen Research & Development, LLC · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 440 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$3,312,000

Rescue Site Savings

+$2,173,500

Unlock Full NCT07746687 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07746687 Rescue Dossier →